Agentura Science Pro spol. s r.o.
- Address
- Dlouha 521/34, 779 00 Lazce, Czechia
Cardiovascular Diseases
At Agentura Science Pro spol. s r.o., clinical research in cardiovascular diseases focuses on people with established cardiovascular disease, high cardiovascular risk, hypertension, and primary prevention of atherosclerotic cardiovascular disease. The trials are designed to test new ways to lower heart-related risk, improve cholesterol control, and support better long-term outcomes.
- Studies evaluating whether new therapies can reduce major cardiovascular events such as heart attack, stroke, and urgent coronary procedures
- Research on improving LDL cholesterol target achievement in people already receiving lipid-lowering treatment
- Trials assessing blood pressure-focused treatment approaches for patients whose hypertension remains difficult to control
This area reflects a strong interest in preventive cardiology, with the goal of identifying treatments that may better protect patients at risk of serious heart complications.
Nutritional and Metabolic Diseases
The site also conducts studies in nutritional and metabolic diseases, especially for obesity and overweight. These trials explore whether emerging therapies can help reduce body weight and improve related health risks, including conditions that often overlap with cardiovascular disease.
- Trials examining weight-management treatments for adults living with obesity or overweight
- Research looking at whether treatment can also influence kidney outcomes and broader cardiometabolic health
- Studies aimed at understanding how new therapies may support healthier weight and reduce disease burden over time
Overall, the research highlights a combined focus on metabolic health and prevention, with attention to both weight-related disease and its impact on heart and kidney outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Agentura Science Pro spol. s r.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial | Metsera Inc. | Phase III | Not Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2022-04-08 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.